Trevi Therapeutics Inc (TRVI)
$17.92
$-0.03
(-0.17%)
As on 26-Aug-2026 16:00EDT
Market cap
$2,559 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
8.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-4.9
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.3
-
Face value
--
-
Shares outstanding
142,475,841
8 Years Aggregate
CFO
$-178.38 Mln
EBITDA
$-184.16 Mln
Net Profit
$-195.46 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Trevi Therapeutics Inc (TRVI)
| 43.1 | 2.2 | 26.8 | 146.2 | 100.3 | 60.0 | -- |
|
BSE Sensex*
| -9.1 | 1.1 | 1.2 | -4.8 | 5.8 | 6.6 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Trevi Therapeutics Inc (TRVI)
| 203.9 | 204.7 | -30.6 | 146.8 | -67.7 | -35.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Trevi Therapeutics Inc (TRVI)
|
17.9 | 2,558.9 | 0.0 | -51.1 | -- | -20.3 | -- | 8.1 |
| 89.1 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 250.3 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 79.2 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.1 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 107.1 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 538.9 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 619.1 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 377.4 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 151.5 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Trevi Therapeutics Inc (TRVI)
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease,... and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut. Read more
-
Co-Founder, CEO, President & Director
Ms. Jennifer L. Good
-
Co-Founder, CEO, President & Director
Ms. Jennifer L. Good
-
Headquarters
New Haven, CT
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Trevi Therapeutics Inc (TRVI)
What is the current share price of Trevi Therapeutics Inc (TRVI) Today?
The share price of Trevi Therapeutics Inc (TRVI) is $17.92 (NASDAQ) as of 26-Aug-2026 16:00 EDT. Trevi Therapeutics Inc (TRVI) has given a return of 100.3% in the last 3 years.
What is the current PB & PE ratio of Trevi Therapeutics Inc (TRVI)?
Since, TTM earnings of Trevi Therapeutics Inc (TRVI) is negative, P/E ratio is not available.
The P/B ratio of Trevi Therapeutics Inc (TRVI) is 8.10 times as on 21-Aug-2026, a 51 premium to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-42.60 |
9.94 |
2024 |
-9.12 |
4.38 |
2023 |
-4.59 |
1.61 |
2022 |
-6.50 |
1.76 |
2021 |
-0.50 |
0.99 |
What is the 52 Week High and Low of Trevi Therapeutics Inc (TRVI)?
The 52-week high and low of Trevi Therapeutics Inc (TRVI) are Rs 20.22 and Rs 6.93 as of 27-Aug-2026.
What is the market cap of Trevi Therapeutics Inc (TRVI)?
Trevi Therapeutics Inc (TRVI) has a market capitalisation of $ 2,559 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Trevi Therapeutics Inc (TRVI)?
Before investing in Trevi Therapeutics Inc (TRVI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.